Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
about
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerDoes dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.A mini-review on factors and countermeasures associated with false-negative sentinel lymph node biopsies in breast cancer.Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials.Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trialsThe role of neratinib in HER2-driven breast cancer.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
P2860
Q26748850-3207484C-5028-4A69-96FD-4FED7CD559A5Q26785612-F41BEDD6-DB01-4E9A-B08F-B0F4D4F412E9Q36281513-32F0E30A-2CAF-4A7B-9143-F97BD3EB6248Q36967905-A4AE9DAE-9DDA-40A0-B5BE-FA03F2984C0DQ37104606-1C823E79-08CA-40A6-8F41-43DBAE9AE58DQ37577947-8EF55F2B-B6D2-4D6E-891D-5B0F1921D5B0Q37612139-E33DD13C-B051-40EE-9479-8F9A7A0F85FFQ37704313-F96857E2-9868-4D49-966D-DE433C91E44CQ38664492-0C566C09-E7BC-43F2-80AA-CCDDEB89DFBEQ38683638-680CEAD2-56AC-4406-99E0-52D61A5D85FFQ38686027-50FAA653-2904-4581-9FDE-7816FFE3B108Q41603225-408C906B-E447-4410-B78A-B8BFC875D704Q49887903-1BBD34DC-6947-432F-B119-00F23C7EF2BDQ55282718-B6AD6F13-C69A-45B1-AD86-8958237A4D60
P2860
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@ast
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@en
type
label
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@ast
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@en
prefLabel
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@ast
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@en
P2093
P2860
P1433
P1476
Neoadjuvant dual HER2-targeted ...... d prospective clinical trials.
@en
P2093
Bhuvaneswari Ramaswamy
Charles Shapiro
Erin R Macrae
Ewa Mrozek
Jenny Querry
Maryam Lustberg
Mellissa Hicks
Rachel Layman
Robert Wesolowski
Susan Friedman
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0334
P577
2015-03-02T00:00:00Z